newsfilter
← Latest News
Business Wire·

Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Results; Achieves 2024 Financial Guidance

– Announced positive data from open-label extension study demonstrating an increased number of patients on apraglutide achieving enteral autonomy over time – – Initiated rolling NDA submission; on track to be